HOME >> MEDICINE >> NEWS
C-reactive proteins: Should everyone be tested?

(Philadelphia, PA) -- In the last year, a number of studies have focused on the C-reactive protein (CRP) inflammatory risk factor for heart disease. Using high-sensitivity assays (hsCRP), we are able to measure CRP at lower levels than previously possible. These low levels of CRP (hsCRP) are related to chronic, low grade inflammation, which is associated with heart disease. Many of these studies reported on the relationship of hsCRP to first myocardial or anginal attack, recurrence of coronary heart disease incidents, and increased prognosis of heart disease when elevated hsCRP exists with other risk factors. Other published materials have focused on the laboratory methods used for identifying hsCRP, and have expressed concern about results that stem from using different test methods to identify hsCRP. A Cardiac Risk Survey released earlier this year by the College of American Pathologists (CAP) underscored the need for standardizing the results of five different classes used by labs to identify hsCRP. The Centers for Disease Control and Prevention (CDC) have issued recommendations to address these concerns.

Presentation at the 55th Annual AACC Meeting

How important is hsCRP as an indicator of cardiovascular disease? What is the role of laboratories and are readings affected by different laboratory methods and a lack of standardization? The Centers for Disease Control and Prevention (CDC) has examined these questions and developed recommendations for the public and leaders of the nation's clinical laboratories.

These recommendations will be discussed by Gerald R. Cooper, MD, PhD, of the Centers for Disease Control and Prevention, Atlanta, GA. Dr. Cooper will deliver his remarks entitled, "C-Reactive Protein: A New Inflammatory Risk Factor for Cardiovascular Disease," during the 55th Annual Meeting of the American Association of Clinical Chemistry (AACC) being held July 20-24, 2003 at the Pennsylvania Convention Center, Philadelphia
'"/>

Contact: Donna Krupa
djkrupa1@aol.com
703-527-7357
American Association for Clinical Chemistry
21-Jul-2003


Page: 1 2 3

Related medicine news :

1. Vitamin C reduces level of C-reactive protein, finds UC Berkeley-led study
2. C-reactive proteins do not predict early osteoarthritis
3. C-reactive protein more than a heart disease marker
4. High levels of C-reactive protein indicate early heart disease
5. Should medical students have earlier contact with patients?
6. Should nurses conduct breast cancer follow-up visits?
7. Should compulsory screening of immigrants be part of UK public health policy?
8. Should the standard guidelines for assessing prostate cancer control be changed?
9. Should living liver donation be available in the NHS?
10. Should ambulance crews perform emergency breathing procedure?
11. Should people with dementia be electronically tagged?

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: reactive proteins Should everyone tested

(Date:8/31/2015)... ... August 31, 2015 , ... For 12 years, since 2004, the ... 26th as Mesothelioma Awareness Day . On this day, and in the weeks ... of becoming involved and helping the cause. , “One of the ways a person ...
(Date:8/31/2015)... ... August 31, 2015 , ... Chicago-based company The Mood ... to raise money and awareness for breast and ovarian health. During September ... incandescent Mood-lite sold to Bright Pink® to encourage households, dorms, and offices around ...
(Date:8/31/2015)... ... 31, 2015 , ... The Brooks Group, a global sales ... department devoted to helping organizations identify and keep the best talent both inside ... Brooks Group believes in offering a solution that goes beyond simply providing assessments ...
(Date:8/31/2015)... ... August 31, 2015 , ... ERT, a leading global provider ... solutions will demonstrate multiple prototypes from its Innovation Lab during its 8th Annual ... the only European event dedicated to providing case studies and pragmatic information on ...
(Date:8/31/2015)... ... August 31, 2015 , ... ... certifies products for the water, food, health sciences and consumer goods industries, has ... for their advanced iron filtration media, Pro-OX Manganese Dioxide. , Developed by a ...
Breaking Medicine News(10 mins):Health News:Cancer Research Organization Paints the World in Mesothelioma Awareness 2Health News:Cancer Research Organization Paints the World in Mesothelioma Awareness 3Health News:Mood-lites® is proud to launch “Brighten Our World" Campaign to Raise Money and Awareness for Breast and Ovarian Health Across America in Partnership with Bright Pink® 2Health News:Mood-lites® is proud to launch “Brighten Our World" Campaign to Raise Money and Awareness for Breast and Ovarian Health Across America in Partnership with Bright Pink® 3Health News:The Brooks Group Introduces Talent Management Division 2Health News:The Brooks Group Introduces Talent Management Division 3Health News:ERT to Demonstrate Innovation Lab Prototypes at European PRO / eCOA Congress 2Health News:ERT to Demonstrate Innovation Lab Prototypes at European PRO / eCOA Congress 3Health News:NSF International Has Recognized Clean Water Systems & Stores Inc Facility 2Health News:NSF International Has Recognized Clean Water Systems & Stores Inc Facility 3
(Date:8/31/2015)... PRINCETON, N.J. , Aug. 31, 2015  /PRNewswire/ ... Company), a late-stage biopharmaceutical company developing products that ... inflammation, oncology and biodefense, announced today it has ... by the Data Review Committee (DRC) earlier this ... SGX942.  SGX942 is a first-in-class innate defense regulator ...
(Date:8/31/2015)... , Aug. 31, 2015  Asterias Biotherapeutics, ... on the emerging field of regenerative medicine, today ... at Chicago -based Rush University ... evaluating activity of escalating doses of AST-OPC1 (oligodendrocyte ... and motor complete cervical spinal cord injury (SCI). ...
(Date:8/31/2015)... and STAMFORD, Conn. , Aug. ... of Eisai Co., Ltd., and Purdue Pharma L.P. announced ... agreement for the development and commercialization of Eisai,s clinical ... antagonist entering Phase III clinical development for the treatment ... the agreement, Eisai and Purdue Pharma will share the ...
Breaking Medicine Technology:Soligenix Announces Completion of Patient Enrollment into its Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients 2Soligenix Announces Completion of Patient Enrollment into its Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients 3Soligenix Announces Completion of Patient Enrollment into its Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients 4Soligenix Announces Completion of Patient Enrollment into its Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients 5Soligenix Announces Completion of Patient Enrollment into its Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients 6Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 2Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 3Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 4Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 5Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 6Eisai and Purdue Pharma Enter Worldwide Collaboration to Develop and Commercialize Lemborexant 2Eisai and Purdue Pharma Enter Worldwide Collaboration to Develop and Commercialize Lemborexant 3Eisai and Purdue Pharma Enter Worldwide Collaboration to Develop and Commercialize Lemborexant 4Eisai and Purdue Pharma Enter Worldwide Collaboration to Develop and Commercialize Lemborexant 5
Cached News: